[1] VILAÇA-FARIA H, SALGADO A J, TEIXEIRA F G. Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson’s disease?[J]. Cells, 2019, 8(2):118.
[2] KALLURI R, LEBLEU V S. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478):eaau6977.
[3] SARKO D K, MCKINNEY C E. Exosomes: origins and therapeutic potential for neurodegenerative disease[J]. Front Neurosci, 2017, 11:82.
[4] CHIVET M, JAVALET C, LAULAGNIER K, et al. Exosomes secreted by cortical neurons upon glutamatergic synapse activation specifically interact with neurons[J]. J Extracell Vesicles, 2014, 3:24722.
[5] YUAN L, LI J Y.Exosomes in Parkinson’s disease: current perspectives and future challenges[J].ACS Chemical Neuroscience, 2019, 10(2):964-972.
[6] SORIA F N, PAMPLIEGA O, BOURDENX M,et al. Exosomes, an unmasked culprit in neurodegenerative diseases[J]. Front Neurosci, 2017, 11:26.
[7] STUENDL A, KUNADT M, KRUSE N, et al. Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies[J]. Brain, 2016, 139(Pt 2):481-494.
[8] DANZER K M, KRANICH L R, RUF W P, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers[J]. Mol Neurodegener, 2012, 7:42.
[9] RANI K, MUKHERJEE R, SINGH E, et al. Neuronal exosomes in saliva of Parkinson’s disease patients: a pilot study[J]. Parkinsonism Relat Disord, 2019, 67:21-23.
[10] JARMALAVĬCIŪTĖ A, TUNAITIS V, PIVORAITĖ U, et al. Exosomes from dental pulp stem cells rescue human dopaminergic neurons from 6-hydroxy-dopamine-induced apoptosis[J]. Cytotherapy, 2015, 17(7):932-939.
[11] FUSSI N, HÖLLERHAGE M, CHAKROUN T, et al. Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy[J]. Cell Death Dis, 2018, 9(7):757.
[12] SI X L, FANG Y J, LI L F, et al. From inflammasome to Parkinson’s disease: does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson’s disease?[J]. Exp Neurol, 2021,336:113525.
[13] BRÜCK D, WENNING G K, STEFANOVA N,et al. Glia and alpha-synuclein in neurodegeneration: a complex interaction[J]. Neurobiol Dis, 2016, 85:262-274.
[14] XIA Y, ZHANG G X, HAN C, et al. Microglia as modulators of exosomal alpha-synuclein transmission[J]. Cell Death Dis, 2019, 10(3):174.
[15] GUO M, WANG J, ZHAO Y, et al. Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease[J]. Brain, 2020, 143(5):1476-1497.
[16] GUI Y X, LIU H, ZHANG L S, et al. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease[J]. Oncotarget, 2015, 6(35):37043-37053.
[17] MCMILLAN K J, MURRAY T K, BENGOA-VERGNIORY N, et al. Loss of microRNA-7 regulation leads to α-synuclein accumulation and dopaminergic neuronal loss in vivo[J]. Mol Ther, 2017, 25(10):2404-2414.
[18] CHEN Y, GAO C, SUN Q, et al. MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson’s disease[J]. Front Aging Neurosci, 2017,9:232.
[19] MA J, SHI X, LI M, et al. MicroRNA-181a-2-3p shuttled by mesenchymal stemcell-secreted extracellular vesicles inhibits oxidative stress in Parkinson’s disease by inhibiting EGR1 and NOX4[J]. Cell Death Discov, 2022, 8(1):33.
[20] CHANG C W, YANG S Y, YANG C C, et al. Plasma andserum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson’s disease[J]. Front Neurol, 2020, 10:1388.
[21] BRUGGINK K A, KUIPERIJ H B, EKHOLM-PETTERSSON F, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease[J]. Neurology, 2011, 77(5):510.
[22] WANG X, YU S, LI F, et al. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease[J]. Neurosci Lett, 2015, 599:115-119.
[23] CAO Z, WU Y, LIU G, et al. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease[J]. Neurosci Lett, 2019, 696:114-120.
[24] GUI Y, LIU H, ZHANG L, et al. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease[J]. Oncotarget, 2015,6(35):37043-37053.
[25] ZHAO Y, YANG G. Potential of extracellular vesicles in the Parkinson’s disease - pathological mediators and biomarkers[J]. Neurochem Int, 2021, 144:104974.
[26] FRASER K B, RAWLINS A B, CLARK R G, et al. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson’s disease[J]. Mov Disord, 2016,31(10):1543-1550.
[27] CHEN H X, LIANG F C, GU P, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson’s disease model by inducing autophagy[J]. Cell Death Dis, 2020,11(4):288.
[28] QU M, LIN Q, HUANG L, et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease[J]. J Control Release, 2018, 287:156-166.
[29] PENG H, LI Y, JI W, et al. Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of Parkinson’s disease[J]. ACS Nano, 2022, 16(1):869-994.
[30] HALL J, PRABHAKAR S, BALAJ L, et al. Delivery of therapeutic proteins via extracellular vesicles: review and potential treatments for Parkinson’s disease, glioma, and schwannoma[J]. Cell Mol Neurobiol, 2016,36(3):417-427.
[31] GARBAYO E, ANSORENA E, LANA H, et al. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys[J]. Biomaterials, 2016, 110:11-23.
[32] REN X, ZHAO Y, XUE F, et al. Exosomal DNA aptamer targeting α-synuclein aggregates reduced neuropathological deficits in a mouse Parkinson’s disease model[J]. Mol Ther Nucleic Acids, 2019, 17:726-740. |
